Tip os
Log ind

Qualcomm chief: This is the future

Top picks in English:

The General Manager of the healthcare division in Qualcomm, the world’s largest wireless technology group, offers his view on how healthcare technology will evolve in the future.


by Leonora Beck
Offentliggjort 20.05.14 kl. 14:31

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Zealand carries out USD 89m IPO in the US

ledelsen i Zealand Pharma.JPG Top picks in English:

Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Genmab accelerates research efforts

Top picks in English:

Genmab will need to identify its next winning ticket in the coming three to four years, and its CEO is fully convinced that the drug is already hiding in the biotech company’s pipeline. The firm is now increasing its R&D budget in a bid to identify the winner.

Novo expands its executive team

Top picks in English:

Novo Nordisk has promoted two of its regional directors to its executive management team, which has undergone a slew of changes in the past year.

Darzalex is still the “star of the show” for Genmab

Top picks in English:

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Bioporto CEO despite growing deficit: ”A fantastic six months”

Top picks in English:

Bioporto’s sales of antibodies and the kidney test NGAL for research use have grown rapidly in 2017. Despite this, the company is forced to downgrade its financial expectations, now expecting a larger deficit for the year. But there is a perfectly good reason for that, explains the CEO.

Forsiden lige nu

Samsung vil nu udvikle originale lægemidler

Samsung BioLogics2.jpg Medicinal & Biotek:

Samsung Bioepis, der ellers er sat i verden for at udvikle biosimilære versioner af de bedst sælgende lægemidler, rykker nu i en ny retning i et samarbejde med japanske Takeda om udvikling af originale lægemidler.

Medico-makkerpar har endelig fundet en amerikansk partner

Medico & Rehab:

Medicoselskabet Pleuratech, som har været til salg i fem år, har nu langt om længe fundet en pengestærk partner til at hjælpe sig med en amerikansk lancering af sit produkt. Man har indgået en licensaftale på et tocifret millionbeløb, skriver Børsen.

Nationalt Genom Center får midlertidigt hjem på Amager

Sygdom & Sundhed:

Krumtappen i regeringen og regionernes arbejde med personlig medicin flytter midlertidigt ind hos Sundhedsdatastyrelsen og Statens Serum Institut.

Biotekselskab vil have nyrekræftmiddel godkendt i første linje

Medicinal & Biotek:

Mens rivalen BMS for nylig skuffede i et klinisk studie inden for nyrekræft, så håber et amerikansk biotekselskab nu at få godkendt sit middel mod sygdommen til patienter, der ikke tidligere har fået medicinsk behandling.

Coloplast-topchef vil hæve barren med kliniske beviser

Medico & Rehab:

Danske Coloplast vil trække et helt nyt konkurrenceparameter ind i medicoindustrien. Fremover skal produkterne bevise deres værd med ny klinisk dokumentation. ”Vi gør det selvfølgelig sværere for os selv, men vi gør det også sværere for alle andre at være med,” lyder det fra topchef Lars Rasmussen.

Medie: Novo-selskab vil udfordre Coloplast

Medico & Rehab:

Britiske Convatec, som Novo Holdings ejer små 20 pct. af, vil tage kampen op mod Coloplast, skriver Børsen. Opskriften vil langt henad vejen være den samme som danskernes.

ANNONCE
ANNONCE


ANNONCE